{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"4.7","value":"2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with neuroblastoma.","id":"OG000","title":"Cohort 3"}],"paramType":"MEDIAN","populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months)","title":"PFS as Determined by the Investigator Using mINRC in Participants With Neuroblastoma","type":"PRIMARY","unitOfMeasure":"Months"}